HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Rockwell Medical, citing a strong outlook for the company. The firm significantly raised the price target for the stock, moving it from $2 to $20. This adjustment reflects an increased confidence in the company's future performance and market position.

The revised price target of $20 represents a substantial increase over the previous target of $2. This change underscores the analyst's bullish stance on Rockwell Medical's potential. The company, listed on NASDAQ under the ticker RMTI, continues to be viewed favorably by the firm.

The decision to maintain the Buy rating alongside the higher price target suggests that Rockwell Medical is expected to deliver significant value to shareholders. The specific drivers behind this revised valuation were not detailed in the analyst note.

Rockwell Medical, Inc. has authorized a 1-for-10 reverse stock split of its issued and outstanding common stock, effective July 1, 2026. The strategic move aims to bring the company into compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The Board of Directors approved the amendment to the Certificate of Incorporation following authorization at the Annual Meeting of Stockholders on June 12, 2026.

Listing and Trading Details

Upon effectiveness at 12:01 a.m. EDT on July 1, 2026, the company's common stock will continue to trade under the symbol "RMTI". The new CUSIP number assigned to the post-split common stock is 774374409. Robert S. Radie, Chairman of the Board at Rockwell Medical, emphasized that maintaining the Nasdaq listing supports enhanced liquidity, broader access to capital, and increased visibility in the marketplace.

Impact on Shareholders and Equity

Every ten shares of the company's common stock issued and outstanding will automatically reclassify into one new share. The reverse stock split will not modify any rights or preferences of the shares, nor will it affect the number of authorized shares or the par value. Proportionate adjustments will be applied to the exercise prices and number of shares underlying outstanding equity awards, warrants, and convertible preferred stock.

Fractional Shares and Exchange Agent

No fractional shares will be issued. Stockholders otherwise entitled to fractional shares will receive a cash payment based on the closing trading price on June 30, 2026. Equiniti Trust Company LLC has been appointed as the exchange agent. Stockholders holding shares via a bank, broker, or nominee will see their positions adjusted automatically without further action, subject to their brokers' specific processes.